RMIT University led a study finding that a new simple blood test that measures the body’s own immune response can improve diagnosis of ovarian cancer. The new study uncovered a specific immune biomarker enabling clinicians to identify whether growths on the ovaries are cancerous or not, without the need for tests such as MRI scans or ultrasounds.
Ovarian cancer is one of the most common gynecological cancers with the highest mortality rate. About 300,000 new cases are diagnosed globally each year with an estimated 60% of women dying within five years after diagnosis.
The Study Logistics
The clinical trial was conducted in two hospitals in Melbourne, Australia, with the results published in Scientific Reports. The study was conducted in collaboration with Monash University, Universiti Kebangsaan, University of Melbourne and Hudson Institute of Medical Research, with clinical trials held at the Royal Women’s Hospital and Epworth Healthcare in Melbourne.
The study was supported by the Women’s Cancer Fund, the Ovarian Cancer Research Foundation Inc., and the John Brunner estate.
Senior Author and Chief Investigator Magdalena Plebanski, RMIT University Professor noted that the test could represent an important diagnostic tool for assessing suspicious ovarian growth prior to operations. She emphasized, “Our new test is as accurate as the combined results of a standard blood test and ultrasound.”
About RMIT University
RMIT University is one of Australia’s original tertiary institutions and enjoys an international reputation for excellence in professional and vocational education, applied research and engagement with the needs of industry and the community.
Magdalena Plebanski, Professor, ECP Director, Biomedical and Health Innovation